DIANTHUS THERAPEUTICS INC
DNTHNASDAQTrading Snapshot
- Day Range
- $108.37 – $112.06
- 52-Week Range
- $19.75 – $114.55
- Volume
- $3.20B
- Avg Volume
- $3.93B
- Shares Outstanding
- 55.9M
- Next Earnings
- Sep 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $761,000
- P/E Ratio
- -845.5
- P/S Ratio
- 3228.9x
- EPS (TTM)
- $-0.53
- Dividend Yield
- 0.00%
Why Investors Own DNTH
- ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About DIANTHUS THERAPEUTICS INC
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate
Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses of $(0.88) per share
Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanismsDNTH312 demonstrated
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.